# US 10,864,231 B2 · Botulinum toxin and colloidal silver particles

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 10,864,231 B2
- Document ID: US10864231B2
- Status: Granted
- Kind: B2
- Application number: 15/508,096
- Filed: 2015-08-28
- Published: 2017-10-05
- Granted: 2020-12-15
- Earliest claimed: 2014-09-02
- Assignees: American Silver, LLC; Dr. Andrew Willoughby Inc.
- Applicants: Andrew J. M. Willoughby; American Silver, LLC; Dr. Andrew Willoughby Inc.
- Inventors: Andrew J. M. Willoughby; Keith William Moeller
- Web page: https://patentgrep.com/patent/US10864231B2

## CPC

- A61K 33/38: Silver; Compounds thereof
- A61K 8/042: {Gels}
- A61K 8/044: {Suspensions}
- A61K 8/19: containing inorganic ingredients
- A61K 8/64: Proteins; Peptides; Derivatives or degradation products thereof
- A61K 8/66: Enzymes
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/10: Dispersions; Emulsions
- A61K 9/19: lyophilised {, i.e. freeze-dried, solutions or dispersions (lyophilised products with subsequent particle size reduction A61K9/14; granules or pellets made by lyphilisation A61K9/1682; solid oral dosage forms made by lyophilisation A61K9/2095; lyophilisation additives A61K47/00)}
- A61K 38/4893: {Botulinum neurotoxin (3.4.24.69)}
- A61K 47/02: Inorganic compounds
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 11/02: Nasal agents, e.g. decongestants
- A61P 15/00: Drugs for genital or sexual disorders (for disorders of sex hormones A61P5/24); Contraceptives
- A61P 17/00: Drugs for dermatological disorders
- A61P 21/00: Drugs for disorders of the muscular or neuromuscular system
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/04: Centrally acting analgesics, e.g. opioids
- A61P 27/02: Ophthalmic agents
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61Q 19/08: Anti-ageing preparations
- A61K 2800/41: Particular ingredients further characterized by their size
- A61K 2800/413: Nanosized, i.e. having sizes below 100 nm
- A61K 2800/882: Mixing prior to application
- A61K 2800/91: Injection
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61Q: SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS

## Abstract

Botulinum toxin is combined with colloidal silver particles to provide improved compositions for use in medical and cosmetic treatments.

## Claims

### Claim 1

An injectable composition comprising botulinum toxin (BTX), colloidal silver particles and water, wherein the composition comprises from 10±5 ppm to 30±5 ppm colloidal silver particles for every 100 units of BTX suspended in the water, and wherein the colloidal silver particles are in the form of a stable and colorless colloidal suspension of silver particles having an interior of metallic silver and an exterior surface of ionic silver oxide, wherein at least 75% of the silver particles have diameters between 0.005 micrometers and 0.015 micrometers.

### Claim 2 (depends on 1)

The composition of claim 1 wherein the BTX is botulinum type A neurotoxin.

### Claim 3 (depends on 1)

The composition of claim 1 wherein the BTX is botulinum type B neurotoxin.

### Claim 4 (depends on 1)

The composition of claim 1 wherein at least 90% of the colloidal silver particles have diameters between 0.005 micrometers and 0.015 micrometers.

### Claim 5 (depends on 1)

The composition of claim 1 wherein the colloidal silver particles comprise metal silver of formula Ag(0) and ionic silver of a formula selected from Ag(I), Ag(II), and Ag(III).